secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenetic Biosciences, Inc. (XBIO)
CIK:        0001534525
Form:       8-K
Filed at:   2026-03-13T23:59:59+00:00
Accession:  0001683168-26-001744
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenetic Biosciences reports 2025 net loss $2.7M, cash $7.9M, advances DNase program
--------------------------------------------------------------------------------

- Net loss $2.7M for FY2025; royalty revenue from Takeda sublicense rose 19% to $3.0M.
- R&D expenses decreased 7% to $3.1M (excl. prior-year impairment); G&A down 20% to $2.7M.
- Ended year with $7.9M cash, up $1.7M from prior year-end, aided by $4.0M October public offering.
- Preclinical data supporting DNase I for NETs in cancers; progressing toward IND submission.
- Pursuing strategic alternatives to maximize shareholder value.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534525/000168316826001744/0001683168-26-001744-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534525/000168316826001744/xenetic_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-001744

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer